The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia

Marilyn Huckans, Alex Mitchell, Shital Pavawalla, Benjamin Morasco, Samantha Ruimy, Jennifer Loftis, Muhamad A. Rifai, Peter Hauser

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Antiviral therapy for chronic infection with HCV is associated with significant neuropsychiatric side effects. Research indicates that patients with mental illness are less likely to receive antiviral therapy, despite limited data regarding the influence of antiviral therapy on psychiatric symptoms in patients with specific psychiatric disorders. The aim of this study was to determine whether antiviral therapy is associated with higher rates of psychiatric symptoms in patients with schizophrenia (SCHZ). Methods: A regional Veterans Healthcare Administration database was used to identify veterans meeting criteria for this retrospective chart review. Patients confirmed to have SCHZ and to have received antiviral therapy for HCV between 1998 and 2006 (n=30) were compared with a control group of demographically matched (age, race and gender) patients with SCHZ who did not receive antiviral therapy (n=30). Clinicians blinded to antiviral therapy status used chart notes to evaluate whether patients exhibited prominent symptoms of SCHZ, depression or mania during a 6 month pre-treatment period, the treatment period and a 6 month post-treatment period (or during equivalent periods for the control group). Results: Groups did not significantly differ in rates of symptoms of SCHZ, depression or mania during any study period. During the treatment period, groups did not significantly differ in rates of emergency room visits or inpatient hospitalizations. Conclusions: Our retrospective chart review suggests that patients with SCHZ experience similar rates of psychiatric symptoms on and off antiviral therapy. Despite limitations and constraints of the methods, our data suggest that SCHZ is not a contraindication to antiviral therapy for HCV.

Original languageEnglish (US)
Pages (from-to)111-119
Number of pages9
JournalAntiviral Therapy
Volume15
Issue number1
DOIs
StatePublished - 2010

Fingerprint

Hepatitis C
Antiviral Agents
Psychiatry
Schizophrenia
Therapeutics
Bipolar Disorder
Depression
United States Department of Veterans Affairs
Control Groups
Mentally Ill Persons
Veterans
Hospital Emergency Service
Inpatients
Hospitalization
Databases

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia. / Huckans, Marilyn; Mitchell, Alex; Pavawalla, Shital; Morasco, Benjamin; Ruimy, Samantha; Loftis, Jennifer; Rifai, Muhamad A.; Hauser, Peter.

In: Antiviral Therapy, Vol. 15, No. 1, 2010, p. 111-119.

Research output: Contribution to journalArticle

Huckans, Marilyn ; Mitchell, Alex ; Pavawalla, Shital ; Morasco, Benjamin ; Ruimy, Samantha ; Loftis, Jennifer ; Rifai, Muhamad A. ; Hauser, Peter. / The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia. In: Antiviral Therapy. 2010 ; Vol. 15, No. 1. pp. 111-119.
@article{091cc74b8b7542aba6ed6a15a48216c4,
title = "The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia",
abstract = "Background: Antiviral therapy for chronic infection with HCV is associated with significant neuropsychiatric side effects. Research indicates that patients with mental illness are less likely to receive antiviral therapy, despite limited data regarding the influence of antiviral therapy on psychiatric symptoms in patients with specific psychiatric disorders. The aim of this study was to determine whether antiviral therapy is associated with higher rates of psychiatric symptoms in patients with schizophrenia (SCHZ). Methods: A regional Veterans Healthcare Administration database was used to identify veterans meeting criteria for this retrospective chart review. Patients confirmed to have SCHZ and to have received antiviral therapy for HCV between 1998 and 2006 (n=30) were compared with a control group of demographically matched (age, race and gender) patients with SCHZ who did not receive antiviral therapy (n=30). Clinicians blinded to antiviral therapy status used chart notes to evaluate whether patients exhibited prominent symptoms of SCHZ, depression or mania during a 6 month pre-treatment period, the treatment period and a 6 month post-treatment period (or during equivalent periods for the control group). Results: Groups did not significantly differ in rates of symptoms of SCHZ, depression or mania during any study period. During the treatment period, groups did not significantly differ in rates of emergency room visits or inpatient hospitalizations. Conclusions: Our retrospective chart review suggests that patients with SCHZ experience similar rates of psychiatric symptoms on and off antiviral therapy. Despite limitations and constraints of the methods, our data suggest that SCHZ is not a contraindication to antiviral therapy for HCV.",
author = "Marilyn Huckans and Alex Mitchell and Shital Pavawalla and Benjamin Morasco and Samantha Ruimy and Jennifer Loftis and Rifai, {Muhamad A.} and Peter Hauser",
year = "2010",
doi = "10.3851/IMP1493",
language = "English (US)",
volume = "15",
pages = "111--119",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "1",

}

TY - JOUR

T1 - The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia

AU - Huckans, Marilyn

AU - Mitchell, Alex

AU - Pavawalla, Shital

AU - Morasco, Benjamin

AU - Ruimy, Samantha

AU - Loftis, Jennifer

AU - Rifai, Muhamad A.

AU - Hauser, Peter

PY - 2010

Y1 - 2010

N2 - Background: Antiviral therapy for chronic infection with HCV is associated with significant neuropsychiatric side effects. Research indicates that patients with mental illness are less likely to receive antiviral therapy, despite limited data regarding the influence of antiviral therapy on psychiatric symptoms in patients with specific psychiatric disorders. The aim of this study was to determine whether antiviral therapy is associated with higher rates of psychiatric symptoms in patients with schizophrenia (SCHZ). Methods: A regional Veterans Healthcare Administration database was used to identify veterans meeting criteria for this retrospective chart review. Patients confirmed to have SCHZ and to have received antiviral therapy for HCV between 1998 and 2006 (n=30) were compared with a control group of demographically matched (age, race and gender) patients with SCHZ who did not receive antiviral therapy (n=30). Clinicians blinded to antiviral therapy status used chart notes to evaluate whether patients exhibited prominent symptoms of SCHZ, depression or mania during a 6 month pre-treatment period, the treatment period and a 6 month post-treatment period (or during equivalent periods for the control group). Results: Groups did not significantly differ in rates of symptoms of SCHZ, depression or mania during any study period. During the treatment period, groups did not significantly differ in rates of emergency room visits or inpatient hospitalizations. Conclusions: Our retrospective chart review suggests that patients with SCHZ experience similar rates of psychiatric symptoms on and off antiviral therapy. Despite limitations and constraints of the methods, our data suggest that SCHZ is not a contraindication to antiviral therapy for HCV.

AB - Background: Antiviral therapy for chronic infection with HCV is associated with significant neuropsychiatric side effects. Research indicates that patients with mental illness are less likely to receive antiviral therapy, despite limited data regarding the influence of antiviral therapy on psychiatric symptoms in patients with specific psychiatric disorders. The aim of this study was to determine whether antiviral therapy is associated with higher rates of psychiatric symptoms in patients with schizophrenia (SCHZ). Methods: A regional Veterans Healthcare Administration database was used to identify veterans meeting criteria for this retrospective chart review. Patients confirmed to have SCHZ and to have received antiviral therapy for HCV between 1998 and 2006 (n=30) were compared with a control group of demographically matched (age, race and gender) patients with SCHZ who did not receive antiviral therapy (n=30). Clinicians blinded to antiviral therapy status used chart notes to evaluate whether patients exhibited prominent symptoms of SCHZ, depression or mania during a 6 month pre-treatment period, the treatment period and a 6 month post-treatment period (or during equivalent periods for the control group). Results: Groups did not significantly differ in rates of symptoms of SCHZ, depression or mania during any study period. During the treatment period, groups did not significantly differ in rates of emergency room visits or inpatient hospitalizations. Conclusions: Our retrospective chart review suggests that patients with SCHZ experience similar rates of psychiatric symptoms on and off antiviral therapy. Despite limitations and constraints of the methods, our data suggest that SCHZ is not a contraindication to antiviral therapy for HCV.

UR - http://www.scopus.com/inward/record.url?scp=77949399477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949399477&partnerID=8YFLogxK

U2 - 10.3851/IMP1493

DO - 10.3851/IMP1493

M3 - Article

C2 - 20167997

AN - SCOPUS:77949399477

VL - 15

SP - 111

EP - 119

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 1

ER -